These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 10963823)
1. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Kaku K; Matsuda M; Urae A; Irie S Diabetes Res Clin Pract; 2000 Aug; 49(2-3):119-26. PubMed ID: 10963823 [TBL] [Abstract][Full Text] [Related]
2. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study. Ma Z; Parkner T; Frystyk J; Laursen T; Lauritzen T; Christiansen JS Diabetes Technol Ther; 2012 Jul; 14(7):589-95. PubMed ID: 22519735 [TBL] [Abstract][Full Text] [Related]
4. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516 [TBL] [Abstract][Full Text] [Related]
5. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253 [TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Home PD; Barriocanal L; Lindholm A Eur J Clin Pharmacol; 1999 May; 55(3):199-203. PubMed ID: 10379635 [TBL] [Abstract][Full Text] [Related]
7. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Weyer C; Heise T; Heinemann L Diabetes Care; 1997 Oct; 20(10):1612-4. PubMed ID: 9314644 [TBL] [Abstract][Full Text] [Related]
8. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Heise T; Hövelmann U; Brøndsted L; Adrian CL; Nosek L; Haahr H Diabetes Obes Metab; 2015 Jul; 17(7):682-8. PubMed ID: 25846340 [TBL] [Abstract][Full Text] [Related]
9. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Heinemann L; Weyer C; Rauhaus M; Heinrichs S; Heise T Diabetes Care; 1998 Nov; 21(11):1910-4. PubMed ID: 9802742 [TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Bolli GB; Luzio S; Marzotti S; Porcellati F; Sert-Langeron C; Charbonnel B; Zair Y; Owens DR Diabetes Obes Metab; 2011 Mar; 13(3):251-7. PubMed ID: 21205115 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus. Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566 [TBL] [Abstract][Full Text] [Related]
12. A comparison of the pharmacodynamic profiles of jet-injected regular human insulin versus conventionally administered insulin aspart in healthy volunteers. Engwerda EEC; Tack CJ; de Galan BE Diabetes Res Clin Pract; 2016 Nov; 121():86-90. PubMed ID: 27662042 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs. Plum A; Agerso H; Andersen L Drug Metab Dispos; 2000 Feb; 28(2):155-60. PubMed ID: 10640512 [TBL] [Abstract][Full Text] [Related]
14. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Lindholm A; McEwen J; Riis AP Diabetes Care; 1999 May; 22(5):801-5. PubMed ID: 10332685 [TBL] [Abstract][Full Text] [Related]
15. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study. Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Jacobsen LV; Søgaard B; Riis A Eur J Clin Pharmacol; 2000 Aug; 56(5):399-403. PubMed ID: 11009049 [TBL] [Abstract][Full Text] [Related]
17. Insulin aspart has a shorter duration of action than human insulin over a wide dose-range. Nosek L; Roggen K; Heinemann L; Gottschalk C; Kaiser M; Arnolds S; Heise T Diabetes Obes Metab; 2013 Jan; 15(1):77-83. PubMed ID: 22882249 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Luzio S; Dunseath G; Peter R; Pauvaday V; Owens DR Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358 [TBL] [Abstract][Full Text] [Related]
19. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Haahr H; Heise T Clin Pharmacokinet; 2020 Feb; 59(2):155-172. PubMed ID: 31667789 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan. Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]